Case Reports
Journal Article
Add like
Add dislike
Add to saved papers

Electroconvulsive therapy in neuroacanthocytosis or McLeod syndrome.

Journal of ECT 2009 March
We present the case of a 24-year-old man diagnosed with a neuroacanthocytosis, obsessive-compulsive disorder, mild-moderate severity depressive disorder, and obsessive personality disorder. He received multiple psychotropic drugs, including neuroleptics, antidepressants, and benzodiazepines with small therapeutic response.Severe and progressive clinical impairment appeared including cognitive deterioration, chorea, tics, lingual dystonic protrusion, Parkinsonism, automutilations, and other behavioral disorders consistent with neuroacanthosytosis. Pharmacological trials were not efficacious, and the patient had medication side effects, so pharmacotherapy was reduced to minimal doses and we began electroconvulsive therapy.When the sessions were finished, the patient's speech was more coherent, although the neuroacanthosytosis was unstoppable in its progression. Thereafter, the patient received continuation electroconvulsive therapy fortnightly for 4 months until he died due the neurodegenerative disorder.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app